Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients
Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients is a PHASE1 clinical asset sponsored by Alzahra Hospital, Iran in Amyotrophic Lateral Sclerosis. SEO and diligence focus: mesenchymal stem cell, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Amyotrophic Lateral Sclerosis
Modality: protein therapy
Target: mesenchymal stem cell
Sponsor: Alzahra Hospital, Iran
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 02, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: mesenchymal stem cell
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis
Condition normalized: Amyotrophic Lateral Sclerosis
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: mesenchymal stem cell
Target normalized: mesenchymal stem cell